Research in Dermatology
Stanford EB Research
Epidermolysis bullosa (EB) is a rare genetic skin disorder that causes extreme skin fragility, leading to recurrent blister formation with even minor trauma. There are three major forms of EB: EB simplex (EBS), Junctional EB (JEB), and Dystrophic EB (DEB). Each type of EB differs in severity and clinical presentation. Caring for all patients with EB requires a multidisciplinary approach.
Stanford Dermatology Department's clinical trials unit is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The unit works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the unit continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
- Paul Khavari Lab - Genome Regulation in Homeostasis and Cancer
- Anthony Oro Lab - Regulation of Epithelial and Hair Growth and Development
- M. Peter Marinkovich Lab - Basement Membrane Zone Biology
- Howard Y. Chang Lab
- Anne Chang Reseach Goup - Human Aging and the Skin including non-melanoma skin cancer
- Jean Tang Lab - Finding New Ways to Treat and Prevent Skin Cancer
- Kevin Wang Lab - Studying fundamental mechanisms controlling gene expression in mammalian cells
- Carolyn Lee Lab - Discovering new oncogenes and tumor suppressor genes in skin cancer
Research in the Department of Dermatology span a wide range of efforts, ranging from clinical trials to molecular translational medicine to fundamental studies in epithelial biology, as embodied in the Stanford Program in Epithelial Biology.